1. | Altmedsresearch | |
2. | sevap476 | |
3. | dunnie36 | |
4. | bluewatercloud | |
5. | janetpysz |
1. | Altmedsresearch | |
2. | sevap476 | |
3. | dunnie36 | |
4. | bluewatercloud | |
5. | janetpysz |
1. | dunnie36 01/25/2018 R.W. Baird reiterates Outperform rating; PT lowered to $253 from $332 |
2. | bluewatercloud 02/12/2018 Intercept Announces Phase 3 REVERSE Trial Evaluating OCA for the Treatment of NASH Patients with Compensated Cirrhosis |
3. | Altmedsresearch 09/12/2017 investigating claims |
4. | Altmedsresearch 04/16/2018 Liver Biopsy Data from POISE Phase 3 Substudy Supports Obeticholic Acid's Ability to Reverse or Stabilize Fibrosis and Cirrhosis in Primary Biliary Cholangitis (PBC) Patients |
5. | Altmedsresearch 02/14/2018 $ICPT Earnings today |